Saturday, September 16, 2017 7:09:34 AM
Pipeline presentation September 2017
Kevetrin, Prurisol, Brilacidin
BioCentury’s “NewsMakers” Conference
September 8, 2017
https://static1.squarespace.com/static/5715352e20c647639137f992/t/59b2f34946c3c498ebfe112e/1504899917915/IPIX+Company+Presentation+BioCentury+NewsMakers+Conference++8Sep2017.pdf
Audio...
https://www.ipharminc.com/s/IPIX-Company-Presentation-AUDIO-BioCentury-NewsMakers-8Sep20171.mp3
=====================
As we near the end of trials, specifically designed through CDA's with large pharmas I expect this to gain much more volatility and quite possibly a decent push up.
Flashing back a bit. So far, 'Innovation Pharmaceuticals Inc. hasn't "missed" on one trial. The following are still as relevant today as they were when they were when written.
One of the many excellent KarinCA posts...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=130326950
Did The Medicines Company Trump Cellceutix And Others In A $1B-Plus Skin Infection Market?
https://seekingalpha.com/article/2422945-did-the-medicines-company-trump-cellceutix-and-others-in-a-1b-plus-skin-infection-market
Cellceutix's Fundamental Strength Outweighs Market Cap
https://seekingalpha.com/article/3270535-cellceutixs-fundamental-strength-outweighs-market-cap
Interview With New Cellceutix President Dr A Bertolino
https://seekingalpha.com/article/3988240-interview-new-cellceutix-president-dr-bertolino
New Oral Psoriasis Drug Tops Cellceutix Catalysts
https://seekingalpha.com/article/4029310-new-oral-psoriasis-drug-tops-cellceutix-catalysts
Cellceutix: A New Standard Of Care In Oral Mucositis In The Making
https://seekingalpha.com/article/4059084-cellceutix-new-standard-care-oral-mucositis-making
http://www.ipharminc.com/stages-of-development/
BooDog Friday, 08/25/17 07:50:28 AM
Re: None
Post # of 196673
Catalyst anticipation building. Technical side priming for a move on up. Stochastics setting up for the move. Thinking shares will begin to be harder to find at these levels very soon.
===========================================
Kevetrin
- Positive primary endpoint and p21 data (Phase 1)
http://www.ipharminc.com/press-release/2016/11/12/assay-results-from-cellceutix-phase-1-clinical-trial-of-kevetrin-for-cancer-show-increased-p21-expression-in-675-of-evaluable-patients
- Orphan drug designation for ovarian cancer
http://www.ipharminc.com/press-release/2016/11/16/cellceutixs-kevetrin-receives-fda-orphan-drug-designation-for-the-treatment-of-ovarian-cancer
- Orphan drug designation for pancreatic cancer
http://www.ipharminc.com/press-release/2016/11/12/cellceutix-receives-fda-orphan-drug-designation-for-kevetrin-for-the-treatment-of-pancreatic-cancer
- Orphan drug designation for retinoblastoma
http://www.ipharminc.com/press-release/2016/11/16/cellceutix-receives-fda-orphan-drug-designmation-for-kevetrin-for-the-treatment-of-retinoblastoma
- Rare pediatric disease designation for retinoblastoma
http://www.ipharminc.com/press-release/2016/11/16/cellceutix-receives-rare-pediatric-disease-designation-from-fda-for-kevetrin-for-the-treatment-of-retinoblastoma
Brilacidin
- B-UP positive top-line data (Phase 2 POC)
http://www.ipharminc.com/press-release/2017/7/13/innovation-pharmaceuticals-phase-2-poc-trial-for-inflammatory-bowel-disease-achieves-induction-of-remission-in-a-majority-of-patients-treated-with-brilacidin
- B-ABSSSI positive top-line data (Phase 2b)
http://www.ipharminc.com/press-release/2016/11/16/cellceutix-announces-positive-top-line-data-from-phase-2b-absssi-trial-single-dose-brilacidin-comparable-to-7-days-of-daptomycin
- QIDP designation for B-ABSSSI
http://www.ipharminc.com/press-release/2016/11/16/cellceutix-antibiotic-brilacidin-receives-qidp-designation-from-fda
- Fast track designation for B-OM
http://www.ipharminc.com/press-release/2016/11/16/fda-grants-fast-track-designation-to-cellceutixs-brilacidin-om-for-oral-mucositis
- MTA extension for prophylactic testing in implanted devices
http://www.ipharminc.com/press-release/2016/11/16/cellceutix-completes-lab-testing-of-brilacidin-for-planned-phase-3-trial-for-acute-bacterial-skin-and-skin-structure-infections
- Formulation stable at room temperature
http://www.ipharminc.com/press-release/2016/11/16/cellceutix-announces-breakthrough-in-the-formulation-of-novel-antibiotic-brlaicidin-plans-studies-to-treat-diabetic-foot-ulcers
- American Society for Microbiology journal publication
http://aac.asm.org/content/early/2014/06/11/AAC.02955-14#corresp-1
Prurisol
- Positive top-line data (Phase 2a)
http://www.ipharminc.com/press-release/2016/11/12/cellceutix-phase-2-trial-of-prurisol-for-mild-to-moderate-psoriasis-meets-primary-endpoint
- Positive primary endpoint (Phase 1)
http://www.ipharminc.com/press-release/2016/11/16/cellceutix-anti-psoriasis-drug-prurisol-meets-primary-endpoint-of-clinical-trial
- 505(b)(2) pathway
http://www.ipharminc.com/press-release/2016/11/17/cellceutix-informed-by-fda-that-505b2-approval-would-be-an-acceptable-approach-for-its-psoriasis-drug
Clinical Trials
1. K-OC (Phase 2a, Recruiting)
https://clinicaltrials.gov/ct2/show/NCT03042702?term=cellceutix&rank=1
2. P (Phase 1, Completed)
https://clinicaltrials.gov/ct2/show/NCT02101216?term=cellceutix&rank=2
3. B-OM (Phase 2, Recruiting)
https://clinicaltrials.gov/ct2/show/NCT02324335?term=cellceutix&rank=3
4. P (Phase 2a, Completed)
https://clinicaltrials.gov/ct2/show/NCT02494479?term=cellceutix&rank=4
5. P (Phase 2b, Recruiting)
https://clinicaltrials.gov/ct2/show/NCT02949388?term=cellceutix&rank=5
6. B-ABSSSI (Phase 2b, Completed)
https://clinicaltrials.gov/ct2/show/NCT02052388?term=cellceutix&rank=6
7. K (Phase 1, Completed)
https://clinicaltrials.gov/ct2/show/NCT01664000?term=cellceutix&rank=7
8. B-UP (Phase 2 POC, Completed)
http://www.ipharminc.com/press-release/2016/11/10/cellceutix-receives-update-on-first-patient-enrollment-in-phase-2-proof-of-concept-study-of-brilacidin-for-ulcerative-proctitis
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=133036320
"Perfection is not attainable, but if we chase perfection we can catch
excellence." Vince Lombardi
Do your research! Play the TA. All posts are my opinion.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM